Autologous antiCD19-transduced CD3+ cells
- Status:
- Red
- Decision Date:
- March 2021
Comments
RED:
- NICE TA677- Autologous anti-CD19-transduced CD3+ cells
for treating relapsed or refractory mantle cell lymphoma. (NHSE commissioned). (Decision date - March 2021).
Red Drug Classifications
- 4: Specifically designated as “hospital only” by product licence or by DH/NICE
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again